Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-IIe347 polymorphism

A method for selecting patients with a risk for a thrombogenic disorder, wherein the method comprises determining in a sample the presence of an amino acid exchange from threonine to isoleucine at position 347 of the Thrombin Activable Fibrinolysis Inhibitor (TAFI) with the amino acid sequence according to SEQ ID NO:1.

A method for identifying a pharmaceutical, preferably an inhibitor of TAFI-Ile347, for the therapy and/or prophylaxis of a thrombogenic disorder, wherein the method comprises the steps of:

• (a) providing TAFI-Ile347 or the TAFI-Ile347 gene,
• (b) providing a test compound, and
• (c) measuring or detecting the influence of the test compound on TAFI-Ile347 or the TAFI-Ile347 gene.

22-24. (canceled)

The method according to claim 26, wherein the thrombogenic disorder includes an atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA) and/or atherosclerotic cerebrovascular disease (CVD).

27-29. (canceled)

A method for adapting the dosage of a medicament for the preventive and/or therapeutic treatment of a thrombogenic disorder, wherein the method comprises

• (d) determining in a sample the presence of an amino acid exchange from threonine to isoleucine at position 347 of the Thrombin-Activable Fibrinolysis Inhibitor (TAFI) with the amino acid sequence according to SEQ ID NO:
• 1 (TAFI-Ile347), and
• (b) adapting the dosage of the medicament according to the result of step (a).

The method according to claim 31, wherein the thrombogenic disorder includes an atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease.